<DOC>
	<DOCNO>NCT00648739</DOCNO>
	<brief_summary>The purpose study determine safety best dose ALXN6000 treat relapse refractory B-CLL MM study ALXN6000 may help immune system fight cancer .</brief_summary>
	<brief_title>Safety Dose Ranging Study ALXN6000 Treat Relapsing Refractory CLL MM</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Relapsing Refractory B CLL MM ECOG performance status 02 Anticipated survival great 6 month . Female patient childbearing potential must agree use two form contraception Patients must standard indication treatment malignancy Is willing able give write informed consent . Absolute neutrophil count ( ANC ) &lt; 1000 x 109/L Platelet count &lt; 50,000 x 109/L Pregnant lactate woman . Prior history autoimmune hemolysis require therapy . Prior history immune thrombocytopenia . Active autoimmune disease require immunosuppressive therapy . Positive Coombs ' Test ( neither Direct Indirect ) Ongoing corticosteroid treatment equivalent mineralocortacoid potency 10 milligram ( mg ) /day prednisone , great , condition . Prior stem cell transplantation within 4 week prior enrollment . Prior chemotherapy applicable malignancy within 30 day enrollment . Neurosurgery cranial radiation therapy within one year enrollment . Clinically significant renal , hepatic heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>CD200</keyword>
	<keyword>Anti-CD200</keyword>
</DOC>